Navigation Links
US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream
Date:1/6/2009

COMMACK, N.Y., Jan. 6 /PRNewswire/ -- In recent controlled studies conducted by Dr. Richard Bloomer, University of Memphis, scientists found that the patented ingredient in Glyc'n Go(TM), GlycoCarn(R), is the first and only proven ingredient to increase levels of nitric oxide (NO) in the body; thereby increasing blood nitrate/nitrate (NOx) in human subjects.

Nitric oxide acts as a vasodilator and enables an increase in blood flow to the skeletal muscles. This is significant to 1.) increasing oxygen and nutrient delivery for cellular energy production and 2.) removing metabolic wastes such as lactic acid and carbon dioxide. The resulting affect of an NO increase is improved performance and recovery.

Glyc'n Go(TM) is formulated in the USA by LIFEXPAND(TM). The sports supplement assists in shuttling fatty acids into the cell's mitochondria, enhancing ATP energy production. In addition to the NO and energy benefits; Glyc'n Go(TM) provides antioxidant functions by diminishing the potentially harmful effects of free radicals and aiding in the reduction of muscle tissue damage due to lactic acid build up.

Glyc'n Go(TM) delivers more pure GlycoCarn(R) per serving than any other GPLC tablet or capsule on the market today. Glyc'n Go(TM) is the only chewable form of GlycoCarn(R) and has been proven to dissolve 26% faster than tablets, enabling the product to enter the blood stream and take effect with maximum efficiency.

Glyc'n Go(TM) addresses the needs of many athletes, from strength and power, to endurance and speed. The multitude of benefits offer a number of uses to the active human body.

Glyc'n Go(TM) is manufactured in the USA by LIFEXPAND(TM), Inc. As a service and commitment to the athletic community, LIFEXPAND(TM) rigorously tests it products, including Glyc'n Go(TM), under strict protocols. Glyc'n Go(TM) is certified banned-substance free by Informed-Choice(TM) and HFL, the world's largest sports regulatory and research lab.

Glyc'n Go(TM) is available from leading supplement retailers in 60 count and 16-count individual serving packets. For more detailed information visit www.glycngo.com or call toll free 1-877-GLYCNGO.

Hi resolution photos and images are available at http://www.creativeimage.com/glycngopress


'/>"/>
SOURCE LIFEXPAND
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. California Legislature Passes Historic HIV Testing Bill (AB 682); AHF Urges Governor to Sign Crucial Lifesaving Legislation
2. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
5. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
6. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
7. Test for Life Commends North Carolina Rules Commission for Implementing CDC Recommendations for HIV Testing
8. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
9. Aida Announces Completion of Anti-Cancer Drug Phase Two Testing
10. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
11. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):